Novel therapies in monoclonal gammopathies

References

• Jemal A, Siegel R, Xu J. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927–37.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, et al.. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15:6–25.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al.. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, et al.. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a Multicenter International Myeloma Working Group Study. Blood. 2009;114 Suppl 1:Abstract 2878.
   Google Scholar
• Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, et al.. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107(8):3098–105.
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBalnc R, Podar K, Davies F, Lin B, Hideshima T, et al.. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17:41–4.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, et al.. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol. 1999;163:380–6.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al.. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia. 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, et al.. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269–76.
   Web of Science ®Google Scholar
• Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41–51.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al.. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008–14.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Gertz M, Hayman S, DetweilerShort K, Buadi F, Dispenzieri A, et al.. Long-term efficacy and duration of response of pomalidomide in patients with relapsed multiple myeloma. Haematologica. 2011;96 Suppl 1:P-300.
   Google Scholar
• Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al.. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970–5.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, Duhamel A, Moreau P, Traulle C, et al.. Phase 2 multicenter, randomized open label study of 2 modalities of pomalidomide plus low-dose dexamethasone (POMD) in patients with multiple myeloma (MM) refractory to both lenalidomide and bortezomib (double refractory). IFM 2009-02. Haematologica. 2011;96 Suppl 1: P-148.
   Google Scholar
• Mark T, Rodriguez M, Shah M, Quinn R, Campbell J, Abdullah R, et al.. ClaPD (Clarithromycin/[Biaxin®], Pomalidomide, Dexamethasone) therapy in relapsed or refractory multiple myeloma. Blood. 2011;ASH Abstract 635.
   Google Scholar
• Palumbo A, Larocca A, Carella AM, et al.. A phase I/II study of pomalidomide-cyclophosphamide-prednisone (PCP) in patients with multiple myeloma relapsed/refractory to lenalidomide. Blood. 2011;ASH Abstract 632.
   Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, et al.. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17(9):2734–43.
   PubMed Web of Science ®Google Scholar
• Siegel DS, Martin T, Wang M, Vij R, Lonial S, Kukreti V, et al.. PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long-term follow-up and subgroup analysis. J Clin Oncol. 2011;29:Abstract 8027.
   Google Scholar
• Papadopoulos KP, Lee P, Singhal S. A phase 1b/2 study of prolonged infusion carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma: updated efficacy and tolerability from the completed 20/56 mg/m2 expansion cohort of PX-171-007. Blood. 2011;ASH Abstract 2930.
   Google Scholar
• Niesvizky R, Bensinger W, Vallone M, Gutierrez A, Kunkel L. PX-171-006: phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory MM: preliminary results. J Clin Oncol. 2009;27(15 Suppl):Abstract 8514.
   Google Scholar
• Badros AZ, Vij R, Martin T, Zonder JA, Wong AF, Woo T, et al.. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency. J Clin Oncol. 2010;28(15 Suppl):Abstract 8128.
   Google Scholar
• Hsi E, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al.. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–84.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, et al.. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–24.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011;154(6):745–54.
   PubMed Web of Science ®Google Scholar